Aster DM Quality Care Ltd.
ASTERDMHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
17 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 17 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20220531 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220819 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221117 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230222 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230602 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230822 | 2023-06-30 | yes | |
| TRANSCRIPT | 20240216 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240604 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240808 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241030 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250210 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250528 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250807 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251114 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260209 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260508 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260812 | 2026-06-30 | yes |
ASTERDM
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 768.65 |
| 52-week range | 537.95 – 869.7 |
| Return 1M | 0.44% |
| Return 3M | -0.05% |
| Return 1Y | 21.5% |
| Return 3Y | 133.88% |
| Return 5Y | 260.11% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 1,311.00 |
| Other income | 37.00 |
| Total income | 1,348.00 |
| Cost of materials consumed | 0.00 |
| Purchases of stock-in-trade | 300.00 |
| Changes in inventories | -9.00 |
| Employee benefit expense | 242.00 |
| Finance costs | 31.00 |
Ownership — 2026-07-13, and the change from 2026-06-30
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.54 | 0.13 |
| institutions foreign | 0.10 | -0.00 |
| institutions domestic | 0.16 | -0.11 |
| mutual funds | 0.16 | -0.11 |
| public | 0.46 | -0.13 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 17 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 2,816.00 | 3,192.00 | 3,262.00 | 3,215.00 | 3,317.00 | 3,711.00 | 974.00 | 1,002.00 | 1,086.00 | 1,050.00 | 1,000.00 | 1,078.00 | 1,197.00 | 1,186.00 | 1,182.00 | 1,311.00 |
| Other income | 18.00 | 9.00 | 14.00 | 9.00 | 9.00 | 8.00 | 4.00 | 49.00 | 35.00 | 33.00 | 31.00 | 33.00 | 28.00 | 28.00 | 36.00 | 37.00 |
| Total income | 2,835.00 | 3,201.00 | 3,276.00 | 3,225.00 | 3,325.00 | 3,719.00 | 978.00 | 1,051.00 | 1,122.00 | 1,083.00 | 1,032.00 | 1,111.00 | 1,225.00 | 1,214.00 | 1,219.00 | 1,348.00 |
| Cost of materials consumed | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of stock-in-trade | 914.00 | 1,018.00 | 963.00 | 1,076.00 | 1,052.00 | 1,116.00 | 230.00 | 225.00 | 245.00 | 232.00 | 218.00 | 247.00 | 271.00 | 270.00 | 259.00 | 300.00 |
| Changes in inventories | -75.00 | -63.00 | -36.00 | -110.00 | -93.00 | -45.00 | 2.00 | 3.00 | -7.00 | 15.00 | 7.00 | -0.00 | -0.00 | -3.00 | 4.00 | -9.00 |
| Employee benefit expense | 995.00 | 1,043.00 | 988.00 | 1,091.00 | 1,130.00 | 1,162.00 | 171.00 | 190.00 | 193.00 | 194.00 | 183.00 | 195.00 | 212.00 | 221.00 | 220.00 | 242.00 |
| Finance costs | 77.00 | 87.00 | 96.00 | 99.00 | 102.00 | 99.00 | 30.00 | 29.00 | 31.00 | 31.00 | 32.00 | 31.00 | 31.00 | 31.00 | 30.00 | 31.00 |
| Depreciation and amortisation | 189.00 | 198.00 | 219.00 | 217.00 | 227.00 | 232.00 | 58.00 | 60.00 | 62.00 | 62.00 | 64.00 | 63.00 | 66.00 | 68.00 | 67.00 | 69.00 |
| Other expenses | 663.00 | 746.00 | 842.00 | 771.00 | 850.00 | 913.00 | 412.00 | 419.00 | 436.00 | 420.00 | 400.00 | 429.00 | 464.00 | 486.00 | 467.00 | 512.00 |
| Total expenses | 2,764.00 | 3,028.00 | 3,071.00 | 3,144.00 | 3,268.00 | 3,477.00 | 902.00 | 928.00 | 960.00 | 954.00 | 905.00 | 964.00 | 1,044.00 | 1,074.00 | 1,047.00 | 1,147.00 |
| Profit before exceptional items and tax | 71.00 | 172.00 | 205.00 | 81.00 | 57.00 | 242.00 | 75.00 | 123.00 | 161.00 | 129.00 | 127.00 | 147.00 | 181.00 | 140.00 | 172.00 | 201.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | -55.00 | 0.00 | 0.00 | 0.00 | 0.00 | -24.00 | -26.00 | -4.00 | -0.00 | -28.00 | 0.00 | -114.00 |
| Profit before tax | 71.00 | 172.00 | 205.00 | 81.00 | 2.00 | 242.00 | 75.00 | 123.00 | 161.00 | 105.00 | 101.00 | 142.00 | 181.00 | 112.00 | 172.00 | 86.00 |
| Current tax | 28.00 | 25.00 | 24.00 | 5.00 | 30.00 | 35.00 | -16.00 | 30.00 | 46.00 | 31.00 | 18.00 | 44.00 | 47.00 | 59.00 | 36.00 | 57.00 |
| Deferred tax | -11.00 | -11.00 | -1.00 | 48.00 | -20.00 | -10.00 | 47.00 | 9.00 | 6.00 | 7.00 | -13.00 | -1.00 | -1.00 | -15.00 | -27.00 | -8.00 |
| Tax expense | 17.00 | 14.00 | 23.00 | 53.00 | 10.00 | 24.00 | 31.00 | 39.00 | 53.00 | 37.00 | 5.00 | 43.00 | 46.00 | 44.00 | 10.00 | 49.00 |
| Profit for the period | 54.00 | 159.00 | 183.00 | 20.00 | -15.00 | 209.00 | -2.00 | 5,152.00 | 106.00 | 64.00 | 86.00 | 94.00 | 121.00 | 59.00 | 154.00 | 29.00 |
| Profit attributable to owners | 46.00 | 139.00 | 171.00 | 5.00 | -31.00 | 179.00 | -24.00 | 5,145.00 | 97.00 | 57.00 | 79.00 | 86.00 | 110.00 | 52.00 | 140.00 | 16.00 |
| Profit attributable to non-controlling interests | 8.00 | 20.00 | 12.00 | 15.00 | 15.00 | 30.00 | 22.00 | 7.00 | 9.00 | 8.00 | 7.00 | 8.00 | 11.00 | 6.00 | 13.00 | 13.00 |
| Other comprehensive income | 63.00 | 33.00 | 25.00 | -3.00 | 28.00 | -0.00 | 21.00 | 0.00 | -0.00 | -0.00 | -2.00 | -0.00 | 0.00 | -2.00 | 3.00 | 0.00 |
| Total comprehensive income | 117.00 | 192.00 | 208.00 | 17.00 | 13.00 | 209.00 | 19.00 | 5,152.00 | 106.00 | 64.00 | 84.00 | 93.00 | 122.00 | 57.00 | 156.00 | 29.00 |
| Earnings per share, basic | 0.93 | 2.80 | 3.43 | 0.10 | -0.62 | 3.60 | -0.48 | 103.34 | 1.94 | 1.14 | 1.59 | 1.67 | 2.13 | 1.02 | 2.72 | 0.31 |
| Earnings per share, diluted | 0.93 | 2.80 | 3.43 | 0.10 | -0.62 | 3.60 | -0.48 | 103.19 | 1.94 | 1.14 | 1.58 | 1.67 | 2.13 | 1.02 | 2.71 | 0.31 |
Annual results, as filed
| Line | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 7,963.00 | 8,738.00 | 8,608.00 | 10,253.00 | 11,933.00 | 3,699.00 | 4,138.00 | 4,643.00 |
| Other income | 35.00 | 38.00 | 50.00 | 51.00 | 78.00 | 25.00 | 148.00 | 126.00 |
| Total income | 7,997.00 | 8,776.00 | 8,658.00 | 10,304.00 | 12,011.00 | 3,724.00 | 4,287.00 | 4,769.00 |
| Cost of materials consumed | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of stock-in-trade | 2,525.00 | 2,864.00 | 2,437.00 | 3,068.00 | 3,812.00 | 928.00 | 920.00 | 1,048.00 |
| Changes in inventories | -105.00 | -229.00 | 112.00 | -177.00 | -280.00 | -12.00 | 18.00 | 1.00 |
| Employee benefit expense | 2,688.00 | 2,904.00 | 2,755.00 | 3,264.00 | 3,965.00 | 676.00 | 760.00 | 848.00 |
| Finance costs | 179.00 | 360.00 | 294.00 | 257.00 | 329.00 | 110.00 | 124.00 | 123.00 |
| Depreciation and amortisation | 306.00 | 586.00 | 618.00 | 641.00 | 780.00 | 220.00 | 249.00 | 264.00 |
| Other expenses | 1,992.00 | 1,941.00 | 2,241.00 | 2,614.00 | 2,871.00 | 1,529.00 | 1,675.00 | 1,845.00 |
| Total expenses | 7,585.00 | 8,426.00 | 8,457.00 | 9,668.00 | 11,477.00 | 3,451.00 | 3,747.00 | 4,129.00 |
| Profit before exceptional items and tax | 412.00 | 350.00 | 202.00 | 636.00 | 534.00 | 273.00 | 540.00 | 639.00 |
| Exceptional items | -2.00 | -20.00 | 0.00 | 0.00 | 0.00 | 0.00 | -50.00 | -33.00 |
| Profit before tax | 410.00 | 330.00 | 202.00 | 636.00 | 534.00 | 273.00 | 490.00 | 607.00 |
| Current tax | 45.00 | 28.00 | 22.00 | 44.00 | 86.00 | 32.00 | 126.00 | 186.00 |
| Deferred tax | -2.00 | -13.00 | 6.00 | -8.00 | -26.00 | 24.00 | 9.00 | -43.00 |
| Tax expense | 43.00 | 15.00 | 27.00 | 36.00 | 60.00 | 57.00 | 134.00 | 143.00 |
| Profit for the period | 367.00 | 315.00 | 178.00 | 601.00 | 475.00 | 212.00 | 5,408.00 | 427.00 |
| Profit attributable to owners | 333.00 | 277.00 | 148.00 | 526.00 | 425.00 | 129.00 | 5,378.00 | 388.00 |
| Profit attributable to non-controlling interests | 34.00 | 38.00 | 30.00 | 75.00 | 51.00 | 82.00 | 30.00 | 39.00 |
| Other comprehensive income | 62.00 | 145.00 | -50.00 | 93.00 | 199.00 | 46.00 | -2.00 | 0.00 |
| Total comprehensive income | 430.00 | 459.00 | 128.00 | 694.00 | 674.00 | 258.00 | 5,406.00 | 427.00 |
| Earnings per share, basic | 6.63 | 5.51 | 2.97 | 10.58 | 8.55 | 2.60 | 107.98 | 7.53 |
| Earnings per share, diluted | 6.62 | 5.50 | 2.97 | 10.57 | 8.54 | 2.60 | 107.85 | 7.52 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 13,646.00 | 14,881.00 | 15,708.00 | 17,991.00 | 6,688.00 | 6,606.00 | 7,808.00 | 8,112.00 |
| Non-current assets | 9,213.00 | 9,960.00 | 10,513.00 | 3,826.00 | 4,590.00 | 4,705.00 | 5,932.00 | 6,164.00 |
| Current assets | 4,433.00 | 4,922.00 | 5,195.00 | 565.00 | 2,098.00 | 1,901.00 | 1,877.00 | 1,948.00 |
| Property, plant and equipment | 3,943.00 | 4,629.00 | 7,884.00 | 2,880.00 | 3,571.00 | 3,628.00 | 3,732.00 | 2,619.00 |
| Capital work-in-progress | 712.00 | 255.00 | 395.00 | 170.00 | 231.00 | 291.00 | 401.00 | 413.00 |
| Goodwill | 1,193.00 | 1,160.00 | 1,195.00 | 264.00 | 264.00 | 264.00 | 264.00 | 264.00 |
| Other intangible assets | 2,768.00 | 3,264.00 | 337.00 | 31.00 | 26.00 | 28.00 | 23.00 | 19.00 |
| Inventories | 1,206.00 | 1,306.00 | 1,509.00 | 111.00 | 114.00 | 92.00 | 92.00 | 91.00 |
| Trade receivables | 2,230.00 | 2,336.00 | 2,355.00 | 233.00 | 262.00 | 258.00 | 313.00 | 307.00 |
| Cash and cash equivalents | 222.00 | 379.00 | 434.00 | 82.00 | 915.00 | 165.00 | 196.00 | 228.00 |
| Total equity and liabilities | 13,646.00 | 14,881.00 | 15,708.00 | 17,991.00 | 6,688.00 | 6,606.00 | 7,808.00 | 8,112.00 |
| Equity | 4,686.00 | 4,860.00 | 4,809.00 | 5,030.00 | 3,602.00 | 3,651.00 | 4,772.00 | 4,834.00 |
| Equity share capital | 497.00 | 500.00 | 500.00 | 500.00 | 500.00 | 500.00 | 518.00 | 518.00 |
| Other equity | 3,649.00 | 3,949.00 | 3,874.00 | 4,060.00 | 2,936.00 | 2,929.00 | 4,015.00 | 4,058.00 |
| Total liabilities | 8,960.00 | 10,021.00 | 10,900.00 | 12,961.00 | 3,086.00 | 2,955.00 | 3,037.00 | 3,278.00 |
| Non-current liabilities | 4,748.00 | 5,365.00 | 5,528.00 | 1,673.00 | 1,997.00 | 2,076.00 | 2,144.00 | 2,299.00 |
| Current liabilities | 4,212.00 | 4,655.00 | 5,372.00 | 871.00 | 1,090.00 | 879.00 | 893.00 | 979.00 |
| Borrowings, non-current | 1,398.00 | 1,312.00 | 1,173.00 | 446.00 | 1,746.00 | 484.00 | 484.00 | 558.00 |
| Borrowings, current | 931.00 | 975.00 | 1,196.00 | 223.00 | 194.00 | 158.00 | 156.00 | 143.00 |
| Trade payables | 2,468.00 | 2,988.00 | 3,258.00 | 459.00 | 512.00 | 426.00 | 488.00 | 482.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 734.00 | 1,834.00 | 818.00 | 158.00 | 202.00 | 425.00 | 319.00 | 656.00 |
| Net cash from investing activities | -447.00 | -972.00 | -419.00 | -885.00 | 6,774.00 | 6,015.00 | -75.00 | -288.00 |
| Net cash from financing activities | -382.00 | -817.00 | -341.00 | 1,053.00 | -6,143.00 | -6,358.00 | -214.00 | -304.00 |
| Purchase of property, plant and equipment | 309.00 | 717.00 | 358.00 | 797.00 | 164.00 | 346.00 | 232.00 | 469.00 |
| Net increase in cash | -79.00 | 66.00 | 62.00 | 332.00 | 832.00 | 82.00 | 31.00 | 63.00 |
| con:CFO.BEFORE_TAX | 766.00 | 1,893.00 | 872.00 | 229.00 | 260.00 | 540.00 | 388.00 | 816.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 32.00 | 59.00 | 54.00 | 71.00 | 59.00 | 115.00 | 69.00 | 160.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 70.00 | 0.00 | 58.00 | 0.00 | 0.00 | 8.00 | 3.00 | 3.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | -4.00 | 9.00 | -1.00 | 47.00 | 1.00 | 2.00 | 1.00 | 1.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 7,563.00 | 7,563.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 28.00 | 17.00 | 0.00 | 0.00 | 30.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-04-29 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 | 2026-07-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 41.88 | 41.88 | 41.88 | 41.88 | 41.88 | 41.88 | 41.89 | 40.38 | 40.39 | 0.40 | 0.40 | 0.40 | 0.40 | 0.54 |
| Domestic institutions | 7.64 | 7.15 | 13.70 | 16.35 | 20.91 | 22.91 | 24.59 | 24.63 | 25.28 | 0.26 | 0.26 | 0.28 | 0.28 | 0.16 |
| Mutual funds | — | — | — | — | — | — | — | — | 23.87 | 0.25 | 0.25 | 0.26 | 0.27 | 0.16 |
| Insurance companies | 0.02 | 0.04 | 0.10 | 0.36 | 0.25 | 0.19 | 0.74 | 0.63 | 0.96 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Foreign institutions | 40.21 | 41.00 | 33.48 | 27.08 | 23.85 | 22.62 | 21.66 | 23.62 | 19.64 | 0.19 | 0.18 | 0.17 | 0.11 | 0.10 |
| Government | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 57.70 | 57.75 | 57.77 | 57.80 | 57.82 | 57.84 | 57.85 | 59.37 | 59.36 | 0.59 | 0.59 | 0.59 | 0.60 | 0.46 |
| Non-institutional | 9.85 | 9.60 | 10.59 | 14.38 | 13.06 | 12.31 | 11.60 | 11.11 | 14.44 | 0.14 | 0.15 | 0.15 | 0.21 | 0.19 |
| Shares outstanding | 499513060 | 499513060 | 499513060 | 499513060 | 499513060 | 499513060 | 499513060 | 518121029 | 518121029 | 518121029 | 518121029 | 518121029 | 518121029 | 871672439 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Aster Clinical Lab LLP | Subsidiaries | Any other transaction, Interest received, Loan, Purc | 376,900,000.00 | 9 |
| Hindustan Pharma Distributors Private Limited | Subsidiaries | Any other transaction, Interest received, Loan, Purc | 215,800,000.00 | 9 |
| Alfaone Medicals Private Limited | Associates | Any other transaction, Loan | 200,000,000.00 | 2 |
| DM Education and Research Foundation | Other related party | Any other transaction, Sale of goods or services | 145,800,000.00 | 4 |
| Sri Sainatha Multi Speciality Private Limted | Subsidiaries | Any other transaction, Interest received, Loan, Purc | 141,900,000.00 | 5 |
| Aster DM Multispecialty Hospital Private Limited | Subsidiaries | Any other transaction, Interest received, Loan | 90,500,000.00 | 6 |
| Malabar Institute of Medical Sciences Limited | Subsidiaries | Any other transaction, Purchase of goods or services | 63,200,000.00 | 4 |
| Dr. Azad Moopen | Key management personnel of entity | Any other transaction, Remuneration | 47,500,000.00 | 2 |
| DM Med City Hospitals (India) Private Limited | Subsidiaries | Any other transaction, Interest received, Loan | 38,500,000.00 | 7 |
| Aster DM Healthcare FZC | Other related party | Any other transaction | 29,300,000.00 | 2 |
| Prerana Hospital Limited | Subsidiaries | Any other transaction, Sale of goods or services | 12,500,000.00 | 5 |
| Mr. Sunil Kumar M R | Key management personnel of entity | Any other transaction, Remuneration | 11,400,000.00 | 2 |
| Dr. Moopens Healthcare Management Services LLC | Other related party | Any other transaction | 10,700,000.00 | 3 |
| Ambady Infrastructure Private Limited | Subsidiaries | Any other transaction, Interest received, Loan, Purc | 10,100,000.00 | 6 |
| Aster Shared Services Centre PVT LTD | Other related party | Any other transaction | 9,900,000.00 | 2 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-12 | Q1FY27 | Read the call | |
| 2026-05-08 | Q4FY26 | Read the call | |
| 2026-02-09 | Q3FY26 | Read the call | |
| 2025-11-14 | Q2FY26 | Read the call | |
| 2025-08-07 | Q1FY26 | Read the call | |
| 2025-05-28 | Q4FY25 | Read the call | |
| 2025-02-10 | Q3FY25 | Read the call | |
| 2024-10-30 | Q2FY25 | Read the call | |
| 2024-08-08 | Q1FY25 | Read the call | |
| 2024-06-04 | Q4FY24 | Read the call | |
| 2024-02-16 | Q3FY24 | __________________________________________________________________________ | Read the call |
| 2023-08-22 | Q1FY24 | Mr. Balachander R | Read the call |
| 2023-06-02 | Q4FY23 | Mr. Balachander R | Read the call |
| 2023-02-22 | Q3FY23 | Mr. Balachander R | Read the call |
| 2022-11-17 | Q2FY23 | Read the call | |
| 2022-08-19 | Q1FY23 | Read the call | |
| 2022-05-31 | Q4FY22 | Read the call |
What they said about it, quarter by quarter
| Topic | Q1FY24 | Q3FY23 | Q3FY24 | Q4FY23 | Q4FY24 |
|---|---|---|---|---|---|
| Capex | And to add wherever the specialties are lacking, trying to get a new doctor, a new specialty want to start, so only those CapEx we incur, nothing more… | So considering all those things and also the Capex investment is very low. | To capitalize on the vast population and low hospital bed densities, we are strategically investing in significant capital expenditure, aiming for tot… | — | Coming over to our capex investments, we have added 550+ beds during the year which includes 286 beds in Whitefield, Bangalore. |
| Capital allocation | — | — | Moving forward, post the successful closing of the proposed transaction, our intention, as published earlier is to distribute between 70% to 80% of th… | So, if you look at – you mentioned about the part being distributed as dividend but if we see Indian assets, they have gone up significantly higher in… | I am delighted to mention that we have distributed ~80% of the receipts from the sale of GCC business, as a special dividend of INR 118 per share, und… |
| Costs | — | — | The strong growth extended across both the Indian and the GCC regions and was further amplified by various cost-saving initiatives as well. | — | — |
| Debt and cash | — | How should we think about the debt evolution in India -- net debt? | GCC net debt stands at USD 155 million as at 31st December 2023 compared to USD 163 million as at 31 March 2023. | When I look at the lease payments from your cash flow statement, it has gone up sharply. | Hospital and clinic segment excluding O&M asset-light hospitals, ROCE rose to 24% from 20.9% in FY23. Matured hospitals saw an impressive increase in … |
| Demand | — | — | Second part is, out of the pipeline of 1,700 beds, how much is it brownfield and greenfield? | — | Identifying the significant demand-supply gap in India's healthcare sector reinforces the confidence in our approach. |
| Guidance | So considering that we expect this quarter to do very well. | Alisha had alluded to some of the empanelment that are open, which we expect to come sometime between quarter 4 of this financial year and quarter 1 o… | Whitefield was a new unit started, the cash burn what we expected compared to that we are doing really well there. | So, when can we anticipate these hospitals to come to a breakeven level and witness positive cash flow? | Is it possible to give some guidance on the price hikes for last year and also outlook for the next year and how ARPOBs are looking like for the next … |
| Margin | It's in the nature of a deferred tax liability provision, it's a non-cash item put below the EBITDA line, and the reason for that is because as the ne… | If I look at GCC and India combined, this loss in 9 months at EBITDA level is around INR 66 crores. | Our operating EBITDA has surged by 24% to INR 415 crores, with EBITDA margins standing at 15% this quarter versus 13.8% in Q3 FY23 due to better perfo… | Is it like around 10 times to 12 times EBIT to EBITDA. | Now, coming to the overall India long-term performance, over the last five years, our India operations have experienced significant growth, with a com… |
| People | — | — | I suppose there is an utilization level reaches to close to 60% to 70% odd, just to get an idea of that, how impactful the contribution is going to be… | Yes, potentially, yes, because we are looking at – for mature hospital utilization of 54%. | Nursing attrition, and shortage of nursing is an industry problem. |
| Pricing | At the same time, there are certain price increase also, we have taken. | — | So, there is a head route to correct the pricing. | On the pricing front, is it a stable environment that you're seeing? | This growth has been achieved through revenue assurance, price increase, and improved case mix. |
| Revenue growth | — | So as on a Y-o-Y basis, the revenue is largely flat and the outpatient seems largely at a decent growth at 7%, 8%, but the revenue per outpatient seem… | Aster DM Healthcare Limited – Investors Conference Call on Q3 and 9M FY24 results Page 5 of 33 As a result, our operating EBITDA has exhibited robust … | — | Our India revenue experienced significant growth during the year with the growth 24% YoY, surging to INR 3,699 crores, supported by addition in bed ca… |
What they said they would do
Sentences in which management set an expectation. Each names the speaker and the page of the transcript it came from.
| Date | Quarter | Who | What they said |
|---|---|---|---|
| 2023-02-22 | Q3FY23 | Mr. Balachander R | As per the previous guidance we've given, we expect to incur around INR 250 crores to INR 300 crores going forward, also considering we have got almost 1,800 beds in pipeline. |